Literature DB >> 2156456

Platelet activation by polymorphonuclear leukocytes exposed to chemotactic agents.

A Del Maschio1, V Evangelista, G Rajtar, Z M Chen, C Cerletti, G De Gaetano.   

Abstract

Human platelets were loaded with aequorin, a Ca2(+)-sensitive photoprotein, and tested in the platelet-ionized calcium aggregometer for simultaneous recording of platelet aggregation and intraplatelet Ca2+ levels both in the presence and in the absence of autologous polymorphonuclear leukocytes. Cells were exposed to one of three chemotactic stimuli: platelet-activating factor (PAF), N-formyl-methionyl-leucyl-phenylalanine (FMLP), or leukotriene B4 (LTB4). Platelets alone aggregated and showed intracellular Ca2+ movement only when exposed to PAF. Amplification of both platelet aggregation and intraplatelet Ca2+ movement was induced by PAF in the presence of leukocytes. Aggregation and intraplatelet Ca2+ mobilization were also observed in the presence of leukocytes activated by either FMLP or LTB4. Both parameters increased with the concentration of the stimuli and/or the number of leukocytes. Platelet thromboxane B2 production was also significantly increased in the presence of leukocytes. Addition of platelets at different times after leukocyte activation resulted in progressively reduced cytoplasmic Ca2+ increase. Cell-free supernatants prepared from FMLP-stimulated leukocytes were able to induce platelet aggregation, thromboxane B2 generation, and Ca2+ mobilization, although at a reduced degree as compared with intact leukocyte addition. The activity of leukocyte supernatants was stable at 37 degrees C for up to 30 min and was suppressed by trypsin inhibitor. Our study indicates that stimulated leukocytes release a soluble enzymatic activity able to activate platelets; cell-to-cell interaction may also play a role in this phenomenon. Platelet-leukocyte interaction could have physiopathological relevance and constitutes a new model for studying old and new platelet inhibitory drugs.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2156456     DOI: 10.1152/ajpheart.1990.258.3.H870

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  20 in total

Review 1.  PAF. A review of its effects, antagonists and possible future clinical implications (Part II).

Authors:  M Koltai; D Hosford; P Guinot; A Esanu; P Braquet
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

2.  Downregulation of human platelet reactivity by neutrophils. Participation of lipoxygenase derivatives and adhesive proteins.

Authors:  J Valles; M T Santos; A J Marcus; L B Safier; M J Broekman; N Islam; H L Ullman; J Aznar
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

Review 3.  Defibrotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders.

Authors:  K J Palmer; K L Goa
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

4.  The effect of aspirin on thrombin stimulated platelet adhesion receptor expression and the role of neutrophils.

Authors:  M L Taylor; M K Ilton; N L Misso; D N Watkins; J Hung; P J Thompson
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

5.  Leukocyte count is associated with increased platelet reactivity and diminished response to aspirin in healthy individuals with a family history of coronary artery disease.

Authors:  Nauder Faraday; Lisa R Yanek; Dhananjay Vaidya; Brian Kral; Rehan Qayyum; J Enrique Herrera-Galeano; Taryn F Moy; Diane M Becker; Lewis C Becker
Journal:  Thromb Res       Date:  2009-01-30       Impact factor: 3.944

6.  Human recombinant platelet phospholipase A2 exacerbates poly-L-arginine induced rat paw edema.

Authors:  G Cirino; C Cicala; L Sorrentino
Journal:  Inflammation       Date:  1994-02       Impact factor: 4.092

7.  Platelet-leukocyte interaction in adhesion to endothelial cells induced by platelet-activating factor in vitro.

Authors:  M Hirafuji; H Shinoda
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

8.  Inhibition by recombinant SLPI and half-SLPI (Asn55-Ala107) of elastase and cathepsin G activities: consequence for neutrophil-platelet cooperation.

Authors:  P Renesto; V Balloy; T Kamimura; K Masuda; A Imaizumi; M Chignard
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

9.  Thrombin-activated platelets promote leukotriene B4 synthesis in polymorphonuclear leucocytes stimulated by physiological agonists.

Authors:  R Palmantier; P Borgeat
Journal:  Br J Pharmacol       Date:  1991-08       Impact factor: 8.739

10.  Interference of anti-inflammatory and anti-asthmatic drugs with neutrophil-mediated platelet activation: singularity of azelastine.

Authors:  P Renesto; V Balloy; B B Vargaftig; M Chignard
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.